An update on the clinical diagnostic value of β-hCG and αFP for intracranial germ cell tumors by Mingming Hu et al.
Hu et al. Eur J Med Res  (2016) 21:10 
DOI 10.1186/s40001-016-0204-2
RESEARCH
An update on the clinical diagnostic 
value of β-hCG and αFP for intracranial  
germ cell tumors
Mingming Hu1†, Hongzhi Guan2†, Ching C. Lau3, Keita Terashima4, Zimeng Jin1, Liying Cui2*, Yuzhou Wang5, 
Guilin Li6, Yong Yao7, Yi Guo7, Yan Michael Li8, Dingrong Zhong9, Juan Xiao10, Xirun Wan11, Xin Lian12, 
Feng Feng13, Haitao Ren2, Yanhuan Zhao2, Xinqi Cheng14 and Feng Gu1*
Abstract 
Background: Pathological examination combined with tumor markers has become a standard for the diagnosis 
of intracranial germ cell tumors (ICGCTs), but the current concept of ‘secreting germ cell tumors’ and three empiri-
cally highly specific diagnostic criteria (β-hCG ≥ 50 IU/L or αFP ≥ 10 ng/mL; β-hCG ≥ 100 IU/L or αFP ≥ 50 ng/mL; 
β-hCG > 50 IU/L or αFP > 25 ng/mL) are not based upon pathology examination or CSF cytology. Further investiga-
tion is needed to re-evaluate their value.
Methods: A multidisciplinary diagnostic team was created. Valid β-hCG/αFP data were collected from cases of 
ICGCTs confirmed by pathology and CSF cytology (n = 58) between 1991 and 2012, and from suspected ICGCTs 
cases (n = 17) between 2011 and 2012 as controls [Langerhans cell histiocytosis (LCH), n = 12; and other intracranial 
tumor (ICT), n = 5]. The cut-off points for β-hCG and αFP were calculated using receiver operating characteristic (ROC) 
curves.
Results: This study clarifies the relative rationality of one criteria (β-hCG > 50 IU/L and αFP > 25 ng/mL); confirms 
new β-hCG diagnostic cut-off points: CSF β-hCG ≥ 8.2 IU/L and serum β-hCG ≥ 2.5 IU/L (sensitivity of 47 and 34 %, 
respectively, specificity of 100 %, both; P < 0.05); and empirically adjusts the criteria for αFP to ≥ 3.8 ng/mL in CSF 
and to ≥ 25 ng/mL in serum. The total diagnostic sensitivity for ICGCTs finally increased from 34.6 to 65.4 % (P < 0.05, 
diagnostic value of CSF β-hCG exceeds 90 %). Subtype diagnosis improved with αFP in 16.7 % of non-geminomatous 
germ cell tumor cases.
Conclusion: New evidence-based criteria of β-hCG and αFP can help improving early and formal diagnosis of 
ICGCTs, and is of great clinical significance.
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Background
Whatever their origin, intracranial germ cell tumors 
(ICGCTs) are classified into germinomas (including 
simple germinomas and syncytial trophoblast giant cells 
(STGCs); >82  % of ICGCTs) and non-geminomatous 
GCTs (NGGCTs) (including embryonal carcinomas, 
yolk sac tumors, choriocarcinomas, teratomas, and 
mixed germ cell tumors) [1]. About 40–46 % of ICGCTs 
are in the pineal region, while 30–42 % are in the sellar 
region [2]. ICGCTs are more common in males than 
females (ratio of about 4 to 1) and generally occur in peo-
ple <30  years old with a peak incidence at 10–12  years 
[3]. Although ICGCTs are quite rare, it was previously 
thought that ICGCTs were more common in Asia than in 
Europe or the USA [1].
Historically, it was found that certain ICGCTs are 
capable of secreting tumor markers such as the β subu-
nit of human chorionic gonadotropin (β-hCG) and/
or α-fetoprotein (αFP). As a result, a 1990s consensus 
defined NGGCTs as “secreting germ cell tumors” [4, 5], 
but this concept has been found to be limited. First, many 
pathologically confirmed cases of germinoma are show-
ing highly variable levels of β-hCG in the cerebrospinal 
fluid (CSF) and serum [6–9]. Secondly, no criteria have 
been agreed upon these levels, but three criteria are used 
for diagnosis and initiating chemotherapy, all three using 
the same levels in either the serum or CSF. These crite-
ria evolved since the 1990s and are (1) β-hCG ≥ 50 IU/L 
or αFP ≥ 10 ng/mL [4, 5, 10–12]; (2) β-hCG ≥ 100 IU/L 
or αFP  ≥  50  ng/mL [13]; and (3) β-hCG  >  50  IU/L or 
αFP  >  25  ng/mL [14]. Finally, these criteria fail to pre-
sent the meaning of differential diagnoses among other 
suspected intracranial lesions located in classical sites 
of ICGCTs (such as the pineal region, the sellar region, 
and the basal ganglia region). More appropriate diagnos-
tic criteria should also help diagnosing the ICGCTs at an 
early stage to avoid a delayed diagnosis [15–18].
Therefore, it is of great clinical significance to re-eval-
uate the clinical diagnostic criteria of β-hCG and αFP 
levels. The aim of this study was to investigate the levels 
of β-hCG and αFP in CSF and serum with pathological 
examination (as the gold standard) in order to improve 
the early and standardized diagnosis of different subtypes 




This study was approved by the Ethics Committee of 
the Peking Union Medical College Hospital (PUMCH). 
As detection of these tumor markers is included in the 
routine clinical laboratory work-up of patients suspected 
with ICGCT, consent to treatment was signed by the 
patients or their guardians, but the committee waived the 
need for individual research consent.
The ICGCT study population included only the cases 
of ICGCT confirmed by histopathology and/or CSF 
cytology and admitted at the PUMCH between March 
1991 and December 2012. Patients were excluded if they 
had already undergone radiation therapy before surgery, 
had been diagnosed only by tumor markers, or had an 
associated intracranial infection.
In the ICGCT group, 26 cases were prospectively col-
lected between September 2011 and December 2012, 
which was defined as the “recent” group, while the cases 
collected between 1991 and 2011 were defined as the 
“past” group. All patients in the recent group had syn-
chronous β-hCG and αFP data, while only part of the 
past group had synchronous available data.
A positive control population was selected from cases 
with pathologically confirmed Langerhans cell histiocy-
tosis sellar region lesions (LCH group, n =  12), includ-
ing four patients with saddle area LCH, and intracranial 
tumors (ICT group, n = 5), all admitted at the PUMCH 
between September 2011 and December 2012. All 
patients in the control group had synchronous β-hCG 
and αFP data.
Study design
A comprehensive multidisciplinary diagnostic team for 
ICGCTs was created before collecting the patients from 
the recent period. The diagnostic algorithm is shown in 
Fig. 1.
The demographic data, tumor site, surgery pattern/sur-
gical access, degree of excision, results of histopathology 
and CSF cytology, and staging of CSF dissemination were 
collected. Both the latest β-hCG and αFP data from lum-
bar puncture CSF and serum were gathered before the 
cases were confirmed in order to examine, compare, and 
evaluate three diagnostic criteria of “secreting tumors” 
through the strategy of exclusion. During this process, 
the data was available but not necessary “synchronous.”
The term “synchronous” had different meanings 
between different groups. In the past group, it meant 
that the interval of obtaining CSF and blood serum sam-
ples was within 24 h. In the recent and control groups, it 
meant that both CSF and blood serum samples were col-
lected at the same time.
“Valid” data were defined for early ICGCT diagnosis by 
exploring the lower cut-off values compared to the cur-
rent criteria. Valid β-hCG data meant that it had to be 
under 50  IU/L for early diagnosis, while valid data for 
αFP (<10, <25, or <50 ng/mL) was only determined after 
the proper criteria by examination of the earlier αFP data. 
Before the cases were confirmed, both the lumbar punc-
ture CSF and serum β-hCG and αFP data were gathered 
Page 3 of 11Hu et al. Eur J Med Res  (2016) 21:10 
to evaluate the three diagnostic criteria of secreting 
tumors according to the pathological and CSF cytologi-
cal results (not all data were synchronous). Measurement 
detection thresholds for β-hCG and αFP were 21 U/L and 
0.605  ng/mL, respectively. Therefore, by adding 2 or 1 
to the treatment data to the original value, the value of 
0 is avoided and can be used with the natural logarithm. 
After being added with 2 (for β-hCG) or 1 (for αFP), both 
groups underwent natural logarithmic transformation 
to observe the distributions of the two tumor markers 
in CSF and blood serum as well as the correlation analy-
sis and the linear regression analysis (all data were syn-
chronous). Two valid groups were selected to combine 
with the β-hCG and αFP data of lumbar puncture CSF 
and serum in the LCH group and the other intracranial 
tumors group for ROC analysis. The possible diagnostic 
cut-off values of β-hCG and αFP were then calculated in 
both CSF and serum. Both cut-off values were compared 
with the diagnostic criteria of secreting tumors to assess 
their diagnostic significance.
Tumor evaluation criteria
Regional classifications: all lesions that involved one kind 
of basal ganglia region were classified as basal ganglia 
lesions, while the others were classified into the pineal 
lesions and sellar lesions. The mixed type was defined by 
two or more non-adjacent lesions but without basal gan-
glia region involvement.
Surgical extent was classified as biopsy (<10  % of the 
lesion), partial resection (PR; 10–49 % of the lesion), total 
resection (GTR; microscopic total resection), and subto-
tal resection (STR, between 50 % and total resection).
Germ cell tumors were classified as NGGCTs and 
mixed germ cell tumors (diagnosed by two or more con-
firmed subtypes, or significantly increased αFP concen-
tration in CSF or blood serum though other tumor cells 
were not clear except for the content of the germinoma).
CSF dissemination staging was classified based on the 
complete absence of tumor cells in the CSF (M0), the 
presence of tumor cells in the CSF (M1), implantation 
metastases with tubercles in the ventricular system or 
cranial subarachnoid space (M2), implantation metasta-
ses with tubercles in the spinal subarachnoid space (M3), 
and extracranial metastases (M4).
Evaluation of tumor markers
The methods for detecting tumor markers changed 
slightly during the study period. The PUMCH kept using 
the ADVIA Centaur Total HCG ReadyPack ELISA kit 
(detection threshold of 2.0  IU/L) for β-hCG that was 
originally provided by Bayer Healthcare Pharmaceuticals 
(Montville, NJ, USA). This test was then acquired by Sie-
mens (Erlangen, Germany) in 2005, without change in the 
detection threshold. The same test was used throughout 
the study period. Initially, αFP was detected by an electro-
chemiluminescence immunoassay (ECLIA) from Roche 
Diagnostics (Basel, Switzerland), and the instrument 
was changed in 2010 to a Cobas 601 (Roche Diagnostics, 
Basel, Switzerland), which uses the same methodology 
and has the same detection threshold of 0.605 ng/mL.
Fig. 1 Diagnostic algorithm for intracranial germ cell tumor (ICGCTs). CSF cerebrospinal fluid, HE hematoxylin and eosin, β-hCG β-subunit of human 
chorionic gonadotropin, αFP alpha fetoprotein, LCH langerhans cell histiocytosis, ICT intracranial tumor
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Statistical analysis
SPSS 22 (SPSS Inc., Chicago, IL, USA) was used for data 
management, statistical analyses, and creating figures. 
Continuous variables are presented as mean ± standard 
deviation or median (range), as appropriate. An inde-
pendent samples t test was applied to pairs of normally 
distributed continuous data. Correlation and linear 
regression analyses were performed on non-normally 
distributed continuous data by adding 2 or 1 (β-hCG: 
+2, αFP: +1) and was transformed by natural logarithm. 
Categorical data were analyzed using the Chi-square test 
(Fisher’s exact probability calculation). ROC curve analy-
sis was applied to determine the diagnostic cut-off values. 
Two-sided P values <0.05 were considered significant.
Results
Characteristics of the patients
There were 26 patients in the recent group and 32 in the 
past group. Significant differences were found between 
the two groups for surgical procedures, tumor sites, and 
pathological classifications. Therefore, the two popula-
tions were divided into two different groups in terms of 
background characteristics (Table 1). No specific seque-
lae or severe disabilities were observed in the two groups.
Only one case in the past group was a mixed tumor 
(contained germinoma and mature teratoma). The recent 
group comprised all ICGCT subtypes including embry-
onal carcinoma, yolk sac tumor, choriocarcinoma, and 
all types of teratoma (mature, immature, and malignant 
transformation) as well as one rare and never reported 
case of pineal intermediate trophoblastic tumor (ITT). 
In addition, one case of mixed pineal tumor was associ-
ated with sellar region pituicytoma. There was no patient 
staged as M4, while only the past group had M3 patients 
that involved the cervical spinal cord as well as cervical, 
lumbar, and sacral nerve roots.
Results of CSF cytology showed germ cell tumors in both 
groups, but the positivity rate was higher in the past group 
than in the recent group; the only case of double lesions in 
the recent group did not show significant imaging changes: 
the pituitary stalk was slightly enlarged and the pineal 
was moderately enhanced. No cytologically positive cases 
by CSF in either group were given after surgery. Patients 
in the recent group were all routinely screened by pineal, 
Table 1 Characteristics of the recent and past groups of patients with intracranial germ cell tumors
NGGCTs non-geminomatous germ cell tumors, CSF cerebrospinal fluid; PR partial resection, STR subtotal resection, GTR total resection, M staging: metastasis staging)
* P < 0.05 recent vs. the past groups
a Both groups showed that the sellar region was the most common site, with a higher proportion in females; in addition to the classic bifocal tumors (sellar and 
pineal), there were other types of bifocal tumors (basal ganglia and sellar region) as well as triple lesions (pineal, sellar, and basal ganglia)
Items Past group (n = 32) Recent group (n = 26)
Patients demographics
 Sex ratio (male:female) 17:15 (1.1:1) 17:9 (1.9:1)
 Age at diagnosis (years), mean ± SD (range)* 19 ± 6.9 (9–41) 12.7 ± 4.3 (6–24)
Tumor characteristics
Pathological classification, n (%) Germinoma 31 (90.6) 17 (65.4)
NGGCTs 0 (0) 2 (7.7)
Mixed type 1 (9.4) 7 (26.9)
Tumor location, n (%)a Pineal 1 (3.1) 4 (15.3)
Sellar 19 (59.4) 10 (38.5)
Basal Ganglia 4 (12.5) 6 (23.1)
Mixed type 8 (25) 6 (23.1)
M staging (cases) M0 (22/16) M1 (4/1) M2 (4/9) M3 (2/0) M4 (0/0)
Method of confirmation
 CSF cytology, n (%) Total cases 14 (43.8) 26 (100)
Positive 9 (64.3) 1 (3.8)
Surgical resection Germinoma NGGCTs Mixed type Total
Biopsy 8/16 0/0 0/2 8/18
PR 7/0 0/0 1/1 8/1
STR 7/1 0/2 0/1 7/4
GTR 0/0 0/0 0/2 0/2
No surgery 9/1 0/0 0/0 9/1
History of radiography (cases) 0/1 0/1 0/1 0/3
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hypothalamic, and pituitary stalk craniotomies as well as 
neuroendoscopic pituitary biopsy. Stereotactic puncture 
was mainly applied to the basal ganglia lesions.
Among controls, there were 12 cases in the LCH group 
(including four cases of solitary sellar lesion), among 
which ten patients were male. Mean age at diagnosis was 
23.1  years (range 9–51). In the ICT group, five patients 
were included (three were male) with a median age at 
diagnosis of 39 (12–57) years. They were two cases of 
craniopharyngioma, one case of sellar region gangli-
oglioma, one case of basal ganglia and pineal region 
primary neuroectodermal tumor, and one case of sellar 
region metastasis of a lung adenocarcinoma.
Tumor markers
In the past group, tumor markers were below the detec-
tion thresholds in 11 cases (34.4  %), markers were 
detected in the serum only in five cases (15.7 %), markers 
were detected in CSF only in one case (3.1 %), and mark-
ers were detected in both the serum and CSF in 15 cases 
(47  %) (including 14 cases of synchronous detection of 
β-hCG and 13 cases of synchronous detection of αFP). 
The mean values (range) of CSF and serum β-hCG were 
113.5 (1.3–1087.5) IU/L and 16.6 (0–224.5) IU/L, respec-
tively, while the numbers of cases with CSF and serum 
β-hCG <50  IU/L were 19 and 17, respectively. Mean 
values (range) of CSF and serum αFP were 4.7 (0.61–
34.3) ng/mL and 3.0 (0.71–15.5) ng/mL, respectively.
In the recent group, 26 cases had synchronous detection 
of β-hCG and αFP in the CSF and serum with mean values 
(range) of CSF and serum β-hCG 171.1 (4–3060) IU/L and 
214.1 (0–4493) IU/L, respectively. There were 13 and 21 
cases with CSF and serum β-hCG <50 IU/L, respectively. 
The mean values (range) of CSF and serum αFP were 7.7 
(0.2–147) ng/mL and 53 (0.8–1013) ng/mL, respectively.
In the LCH group, the mean values (range) of CSF and 
serum β-hCG were 4.3  IU/L (2–6) and 0, respectively, 
while CSF and serum αFP were 0.55 ng/mL (0.2–0.7) and 
2.5 ng/mL (1.0–5.4), respectively.
In the ICT group, the mean value (range) of β-hCG in 
the CSF was 4.4 (3–8) IU/L, while was 0 in the serum. The 
mean value (range) of CSF αFP was 0.68 (0.61–0.8)  ng/
mL, and was 2.7 (1.3–6.1) ng/mL in the serum.
Since the mean values of αFP did not differ greatly 
between the two groups, we combined all values of αFP to 
calculate the mean value (range), which was 0.59 (0.2–0.8) 
ng/mL in the CSF and 2.55 (1–6.1) ng/mL in the serum.
Evaluation of the current diagnostic criteria
Since the three diagnostic criteria of secreting tumors are 
all empirical, no sensitivity or specific data were available. 
However, in this study, we aimed to ensure a diagnostic 
specificity of 100  % in order to lower the misdiagnosis 
rate to the utmost extent. For the entire diagnosis proce-
dure, we adopted the “exclusion method.”
For example, in five cases eventually diagnosed with 
secreting tumors, three (cases 1–3) had CSF β-hCG levels 
<100 IU/L and four (cases 1–4) had β-hCG serum levels 
<100 IU/L; hence, diagnostic β-hCG levels >50 IU/L was 
more rational. However, two cases (cases 1 and 2) had 
CSF and serum β-hCG levels <50  IU/L; so even β-hCG 
levels >50  IU/L were not able to replace the pathologi-
cal examination, but might help avoiding misdiagnosis 
(Table 2).
The lowest criterion for αFP diagnosis as secreting 
tumors was 10 ng/mL. Therefore, two of these cases (cases 
1 and 2) were initially considered as NGGCTs (secreting 
tumors), but the final pathological diagnosis proved them 
to be germinomas. Moreover, since the three remaining 
cases (cases 3–5) had CSF/serum αFP levels of 25–50 ng/
mL and were diagnosed as NGGCTs, the αFP threshold of 
>25 ng/mL was relatively rational.
Correlation between CSF levels and serum tumor markers 
levels in synchronized samples
A total of 40 pairs (14 pairs from the past group and 26 
pairs from the recent group) of synchronous data of CSF 
and serum β-hCG were used to plot a scatter diagram 
(Fig. 2a), which was linear after logarithmic transforma-
tion and was statistically significant (r = 0.852, P < 0.05). 
β-hCG levels were higher in the CSF than in the serum. 
When compared to the NGGCTs subgroups (including 
Table 2 Empirical examination on the diagnostic criteria for secreting tumors




Serum β-hCG CSF αFP (ng/mL) Serum αFP CSF cytology Histopathology Final diagnosis
1 20 3 0.7 15.5 NEG GERM GERM
2 20 4.5 2.4 11.4 NEG GERM GERM
3 61 12.1 3.8 33.5 NEG GERM MIXED
4 252 28.9 8.6 33.5 NEG EMB EMB
5 204.6 204.6 19.1 35.6 NEG MIXED MIXED
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the mixed tumors), the germinoma subgroup showed a 
more significant linear trend.
Figure 2b shows 39 pairs of synchronous data of CSF and 
serum αFP with a linear correlation αFP levels in the CSF 
being significantly lower than in the serum. The difference 
between the germinoma subgroup and NGGCTs was not 
as significant as compared to that of Fig. 2a.
Calculation of the cut-off values of different tumor markers 
in CSF and serum by ROC curve
From Figs.  2 and 3, it was apparent that both CSF and 
serum should not have the same cut-off values. When 
calculating the diagnostic cut-off value of CSF β-hCG, 
priority was given to distinguish significant clinical 
Fig. 2 Scatter diagrams representing the relationship between synchronously sampled tumor markers in the cerebrospinal fluid (CSF) and serum. 
The tumors are classified as germinoma (GERM, red marks) and NGGCTs (green marks ). a Relationship between β-subunit of human chorionic gon-
adotropin (β-hCG) levels (n = 40, r = 0.852, P < 0.05). b Relationship between alpha fetoprotein (αFP) levels (n = 39, r = 0.788, P < 0.05)
Fig. 3 Receiver operating characteristic (ROC) curve analysis of cut-off values for diagnosing intracranial germ cell tumors (ICGCTs). a Cerebrospinal 
fluid (CSF) β-subunit of human chorionic gonadotropin (β-hCG). b Serum β-hCG
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differences between ICGCTs and LCH, craniopharyngi-
oma, and other tumors.
Figure  3a shows that the use of β-hCG levels in CSF 
to diagnose ICGCTs was of statistical significance 
(P < 0.05). β-hCG cut-off points had a 100 % specificity 
at 8.15, 8.65, and 9.75 IU/L. We finally selected ≥8.2 IU/L 
(the most close value to 8.15) as the diagnostic cut-off 
value, and sensitivity and specificity were 47 and 100 %, 
respectively.
The calculation of the diagnostic cut-off value of serum 
β-hCG included data from 55 cases (Fig.  3b). Figure  3b 
shows a statistical significance of serum β-hCG levels for 
diagnosing ICGCTs (P  <  0.05), but the cut-off value was 
not the same as in the CSF. Since the serum β-hCG levels 
in the non-ICGCTs group were all 0 (taking into account 
the detection sensitivity of 2.0 IU/L), the lowest highly spe-
cific diagnostic cut-off value of ≥2.5 IU/L (serum β-hCG 
cut-off points had a 100  % specificity at 1.85, 2.45 IU/L, 
and 2.5 was the most close value to 2.45 while above sen-
sitivity—2.0 IU/L) was the only choice to obtain a 100 % 
diagnostic specificity, resulting in a sensitivity of 34 %.
The calculation for αFP was slightly different from that 
used for β-hCG because the cut-off value of αFP was con-
sidered reasonable at 25 µg/dL, but also because the ROC 
curve was plotted based on all 57 valid cases. Although 
no statistically significant diagnostic cut-off values had 
been found from Fig.  4a, the lowest presumed corre-
sponding cut-off value of CSF αFP levels with 100 % diag-
nostic specificity was 1.1 ng/mL.
The ROC curve was inapplicable because there was 
an inadequate amount of valid data of αFP to calculate 
the diagnostic cut-off values in CSF or serum, but it was 
possible to perform further empirical deduction. If the 
serum diagnostic levels of αFP remained at ≥25 ng/mL, 
the CSF αFP could be downgraded. Based on αFP lev-
els of the three cases (they were 3.8, 6.3, and 8.6 ng/mL, 
respectively) of the recent group, the diagnostic criterion 
of CSF αFP was finally identified as being ≥3.8 ng/mL by 
combining the calculated mean value of αFP of 0.59 ng/
mL in the control group as well as the detection sensitiv-
ity of αFP of 0.605 ng/mL.
Table  3 shows the new clinical diagnostic criteria of 
CSF and serum β-hCG and αFP, in comparison with the 
currently accepted diagnostic criteria (β-hCG > 50 IU/L, 
αFP > 25 ng/mL). Table 3 also shows that after using the 
new criteria, the diagnostic sensitivity of β-hCG in both 
CSF and serum was significantly increased and the CSF 
β-hCG sensitivity was improved the most. The diagnostic 
sensitivity of αFP in the CSF increased without any statis-
tical significance.
When taking into consideration that both β-hCG and 
αFP may at the same time show positive levels (overlap 
factor), the total diagnostic sensitivity of tumor markers 
for the recent group increased from 34.6 % (9/26 cases) 
to 65.4 % (17/26 cases), among which the major propor-
tion should be attributed to the CSF β-hCG levels (61.5, 
94 % cases involved in recent group). Although the diag-
nostic sensitivity of αFP was lower than that of β-hCG, in 
Fig. 4 Receiver operating characteristic (ROC) curve analysis of cut-off values for diagnosing intracranial germ cell tumors (ICGCTs) a by cerebrospi-
nal fluid (CSF) alpha fetoprotein (αFP) levels and b by serum αFP
Page 8 of 11Hu et al. Eur J Med Res  (2016) 21:10 
the recent group, there were still 16.7 % (1/6 case) diag-
nosed as mixed ICGCTs and classified into different sub-
types based on the serum αFP levels.
Discussion
Evaluation of the clinical diagnostic value of β-hCG and 
αFP for ICGCTs is an interesting and confusing topic 
for endocrinologists, neurologists, and neurosurgeons, 
and especially for pediatric oncologists. By establishing a 
multidisciplinary diagnostic team, this study might have 
established a comprehensive and practical way to solve 
the problem.
Although the first case was diagnosed by pathologi-
cal examination in 1991 at the PUMCH, since then, the 
suspected cases at the PUMCH were mainly diagnosed 
by diagnostic radiography. However, since the establish-
ment of a comprehensive diagnostic team, we diagnosed 
26 cases of ICGCTs in less than 2 years. These cases were 
similar to those in other countries in terms of epidemiol-
ogy with the male-to-female ratio of 1.9:1 and mean age 
of 12.7 ±  4.3 years. In addition, all subtypes have been 
observed in this study. The frequency of germinoma was 
65.4  % and the frequency of sellar lesions was 38.5  %. 
Moreover, this study found a rare case of ITT, which 
had not been reported before [19], rather than just study 
its molecular biology [20, 21]. Secondly, this compre-
hensive team helped avoid misdiagnosis or mistreat-
ment caused by relying only on diagnostic radiography 
(especially in solitary sellar LCH cases). Finally, in this 
study, the representative sample of ICGCTs also had the 
typical presentation of β-hCG and αFP levels. Since the 
highest levels of CSF β-hCG were 6 and 8 IU/L in LCH 
and craniopharyngioma cases, this indicated that these 
tumor markers in the control group were of diagnostic 
value.
Although no researchers have given a reasonable 
explanation of the slight increase of β-hCG levels in 
LCH and other cases, it is still possible to conclude that 
the syncytial trophoblast giant cells (STGC) are not the 
only source of endogenous β-hCG. In fact, this may be 
related to the detection methods of β-hCG. Although 
hCG is a glycoprotein with a molecular weight of about 
45  kD and has α and β subunits, the germinoma may 
also independently secrete the β subunit in the free 
form. Therefore, the National Academy of Clinical Bio-
chemistry (NABC) emphasizes that the detection of 
β-hCG should include the whole hCG and free β sub-
unit at the same time [22]. Furthermore, some tumors 
such as trophoblastic tumors of the ovary, gastrointes-
tinal tract, and head and neck may produce hCG, they 
express moderate levels of β-hCG, and the detection 
of β-hCG may suffer from false-positive results. The 
increase of CSF β-hCG in craniopharyngioma reported 
by Honegger et al. [23] was caused by the detection of 
β-hCG rather than whole hCG (detected by immunora-
diometric assay).
In this study, we have for the first time shown the rela-
tive rationality of β-hCG  >  50  IU/L or αFP  >  25  ng/mL 
using an exclusion strategy. Gonzalez-Sanchez [8] and 
Allen et al. [7, 9] showed that CSF β-hCG levels ≥50 IU/L 
were too high and might result in missed diagnoses of 
ICGCTs, highlighting the need to develop more optimal 
diagnostic criteria.
In 2012, Qaddoumi et al. [21] proved for the first time 
that both β-hCG and αFP had logarithmic linear correla-
tions in CSF and serum, and the total effect showed that 
β-hCG levels were higher in the CSF compared to the 
serum, but that αFP was higher in the serum (without 
stated detection method or sensitivity). This study drew 
the same conclusion and further inferred that for these 
two tumor markers, different diagnostic criteria should 
be used in the CSF or the serum. In this study, β-hCG 
and αFP levels were more significant in diagnosing early 
ICGCTs in the CSF rather than in the serum.
In this study, the obtained 8.2 IU/L threshold was quite 
close to that obtained by Allen [5, 7] (6.8  IU/L, ranging 
within 1.6–18.7). Nevertheless, the latter only analyzed 
60 cases of germinomas, their β-hCG levels were all 
lower than 50  IU/L, and they did not plot ROC curves 
against a control group to improve the diagnostic criteria 
(neither did they state the detection method).
In the normal population, according to the reports 
of Gonzalez-Sanchez [8] and Tian et  al. [24], the upper 
limit of the 95  % confidence interval for CSF β-hCG 
levels was 0.688–0.7  IU/L and the maximum value was 
0.8–1.330  IU/L (both detected by Roche ECLIA with a 
detection threshold of 0.1  IU/L). Therefore, consider-
ing the consistency among major detection corporations 
and the marked difference between the normal value and 
8.2 IU/L, the cut-off value obtained in this study was sig-
nificant enough to distinguish between suspicious and 
real ICGCTs cases.
Table 3 Comparison of diagnostic sensitivity between β-hCG 
and αFP of CSF and blood serum in ICGCTs
ICGCTs intracranial germ cell tumors, CSF cerebrospinal fluid, β-hCG β-subunit of 
human chorionic gonadotropin, αFP alpha fetoprotein
* P < 0.05; # recent group
a Fisher’s exact test
n Old criteria (%) New criteria (%) Pa
CSF β-hCG 42 23.8 59.5 0.002*
Serum β-hCG 44 22.7 43.2 0.034*
CSF αFP 41 9.8 17.1 0.259
Serum αFP 40 12.5 12.5 –
Total sensitivity# 26 34.6 65.4 0.026*
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The cut-off β-hCG value of 2.5  IU/L obtained from 
serum in ICGCTs seemed to overlap with the normal 
range <5–10 IU/L [22], but according to the recommen-
dations of the NABC, the age and sex differences of the 
patients should be taken into consideration since the 
upper limit was 5 and 3  U/L for menopausal and men-
strual females, respectively, and 0.7 and 2.1 U/L for males 
aged under and over 50 years, respectively, when using a 
highly sensitive method [22].
In contrast to the calculation for β-hCG, since only a 
few ICGCT secreted αFP, this study failed to obtain pre-
cise diagnostic criteria, but inference analysis revealed 
that serum levels of 25 ng/mL and CSF levels of 3.8 ng/
mL could be used. Although most liver cancers, 10–30 % 
of intestinal tumors, and even benign liver lesions (such 
as hepatitis) cause increase serum αFP, they rarely asso-
ciate with ICGCTs [25]. According to the study by Qin 
et  al. [26], the normal 95  % upper limit of serum levels 
for Chinese Han people was only 5.76  ng/mL and was 
positively correlated with age. Therefore, unless new 
evidence-based cut-off values are found, 25 ng/mL might 
be a reasonable threshold. For CSF αFP levels, Shi et al. 
[27] reported a normal 95 % upper limit of 0.968 ng/mL 
(detected by Roche ECLA with a detection threshold of 
0.605 ng/mL). This value is quite close to the cut-off value 
of 1.1  ng/mL observed in Fig.  4. Therefore, considering 
the important differences between 1 and 3.8 ng/mL, the 
diagnostic level of αFP should be decreased when using 
3.8 ng/mL.
The new criteria not only markedly increased the 
clinical diagnostic rate of ICGCT (the diagnostic sen-
sitivity rose from 34.6 to 65.4 %) and helped early diag-
nosis (decreasing the diagnostic criteria of β-hCG and 
αFP should increase the early treatment rate), but it 
also emphasized the important value (over 90 %) of CSF 
β-hCG levels in the diagnosis and the complementary 
role of αFP (improving the subtype diagnosis in 16.7  % 
NGGCTs cases). This procedure should be given atten-
tion in clinical practice.
Because the sensitivity of the clinical diagnostic value 
of αFP and β-hCG for ICGCTs is still not high enough, 
new markers have been investigated such as CSF micro-
RNA 371–371 and 302 levels, which were significantly 
increased in ICGCTs, but decreased significantly after 
treatment; therefore, this marker might be used for fur-
ther identification of germinoma and NGGCTs [10]. 
Although microRNAs show some promising value, the 
αFP and β-hCG levels are currently irreplaceable.
This study has some limitations. First, only a few 
controls were included and future studies should also 
include suspected ICGCTs cases (such as pineal blas-
toma, pineocytoma, glioma [28] or lymphoma or 
glioma of the basal ganglia region [29]) or children’s 
craniopharyngioma of the sellar region [30, 31]. Sec-
ond, we did not explore the distribution of the αFP 
and β-hCG levels when the brain-blood barrier is 
injured. Third, we did not compare the relationship 
between high β-hCG levels (which may cause a β-hCG-
dependent precocious puberty in boys or hypogon-
adotrophin-hyperandrogenemia in older male cases) 
and the new diagnostic criteria. Fourth, the number of 
patients was relatively small and these results should be 
confirmed using multicenter studies. Finally, we chose 
to set the specificity to 100 % to lower the misdiagnosis 
rate to the utmost extent, which resulted in a lower sen-
sitivity. Nevertheless, additional studies on additional 
markers such as microRNAs should be performed to 
improve the sensitivity.
Conclusions
In conclusion, using a multidisciplinary diagnostic team 
and based on results of histopathology and CSF’s cytol-
ogy, we successfully determined the clinical diagnos-
tic criteria of β-hCG and αFP in CSF and serum, which 
may greatly advance the early and formal diagnosis of 
ICGCTs.
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